Skip to content

Impact of the COVID-19 Epidemic on Glycemic Balance and the Level of Stress in Diabetic Patients

Study of the Changes in Glycemic Control and Psychological Distress in Diabetic Patients After the Confinement Period Related to the COVID-19 Epidemic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04924673
Acronym
COVIGLYSTRESS
Enrollment
202
Registered
2021-06-14
Start date
2020-06-17
Completion date
2021-04-22
Last updated
2021-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

COVID 19, Diabetes, Stress, HbA1c

Brief summary

Prospective, non-interventional, multicentric study

Detailed description

The rapid spread of the COVID-19 pandemic and the isolation at home implemented in France, creates unprecedented challenges for diabetic patients. Patients with diabetes have been considered to be at higher risk of infection by the virus, with a greater risk of mortality; this has been a great source of anxiety for them. It is well known that stress has an impact on plasma glucose levels. The French situation where a general confinement has been decreed over the whole territory (which is not the case for all countries) and for a period of two months, makes it possible to study the impact of this unique situation on stress, sedentary lifestyle, changes in diet and decrease in physical activity. There are no similar experiences described in the literature. The investigators hypothesize there will be an increase of HbA1c in the coming months. The main objective is to assess changes in glycemic control in diabetic patients after the confinement period. The secondary objectives are to: * Evaluate the prevalence of a state of psychological distress (which could be described as post-traumatic) following this epidemic situation in a population of patients with diabetes and to determine the main characteristics of patients with such a state of psychological distress. * Study the evolution of the psychological state at a distance from confinement (6 months later) with the same questionnaire. * Analyze characteristics of lifestyle during confinement: food (snacking), frequency of leaving home, sleep disorders and assess a possible association with variations in HbA1c. This is an observational, prospective, multicenter study. Participation in the study will be offered to all consecutive patients seen in Diabetes consultations, who meet the selection criteria.

Interventions

None listed

Sponsors

Pr Pierre-Henri Ducluzeau, University of Tours, France
CollaboratorUNKNOWN
Rennes University Hospital
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (≥ 18 years old) * Diabetic patient (type 1 or type 2) regardless of their diabetes treatment who experienced complete confinement in their own home, in France. * Patients who had a measured HbA1 or an estimated HbA1c with a glucose sensor Freestyle libre with a known result, between November 1, 2019 and February 29, 2020. * Patients agreeing to have their HbA1c measured between May 15 and July 31, 2020. * Having been informed of the study and not objecting to participating in it

Exclusion criteria

\- Adults over the age of legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty.

Design outcomes

Primary

MeasureTime frameDescription
HbA1cBaselineThe change in HbA1c over the first confinement period as compared to the value in early 2020.

Secondary

MeasureTime frameDescription
StressBaselineThe level of stress as assessed by the GHQ questionnaire and the prevalence of a state of psychological distress (defined by a Likert index in the GHQ test 12 ≥14) both evaluated after the first confinement period in France and then 6 months later, in this population of diabetic patients.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026